TAG vaccine

TAG vaccine is an autologous tumor cell-based cancer vaccine developed by Mary Crowley Medical Research Center in collaboration with Gradalis. The therapy is produced by harvesting a patient's own tumor cells and genetically modifying them via electroporation with a dual-expression plasmid. This plasmid encodes the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene and an antisense sequence targeting transforming growth factor beta-2 (TGF-β2). The vaccine is designed to stimulate a systemic anti-tumor immune response by using GM-CSF to recruit and activate dendritic cells at the injection site, while the antisense component blocks the production of TGF-β2, a potent immunosuppressive cytokine often secreted by tumors to evade immune detection. It has been evaluated in Phase I clinical trials for patients with advanced metastatic solid tumors and carcinomas who have failed standard therapies.

Other names

TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccineAuto TAG vaccine